Lipoprotein Insulin Resistance Index: A Lipoprotein Particle-Derived Measure of Insulin Resistance

This observational validation study developed and validated the Lipoprotein Insulin Resistance Index (LP-IR) — a composite score derived from six NMR-measured lipoprotein parameters that characterize the lipoprotein phenotype of insulin resistance without directly measuring insulin or glucose.

LP-IR showed strong correlation with HOMA-IR and glucose disposal rate (GDR from hyperinsulinemic-euglycemic clamp), outperforming traditional lipid measures (triglyceride/HDL ratio) as an insulin resistance proxy. LP-IR could identify insulin-resistant individuals even with normal BMI or normal fasting glucose — addressing the key limitation of fasting glucose-based screening.

The clinical relevance is in identifying metabolic phenotype in patients who may not yet qualify for a diabetes or prediabetes diagnosis but who have the atherogenic, pro-inflammatory lipoprotein pattern of insulin resistance. These patients — often with normal glucose but elevated small LDL-P, low large HDL-P, and high VLDL-P — have cardiovascular risk that LDL-C substantially underestimates. LP-IR, obtained from a standard NMR lipoprotein panel, quantifies this risk.

LP-IR is not routinely ordered and is not yet incorporated in mainstream cardiovascular risk algorithms. Its use is currently limited to patients where metabolic phenotype evaluation adds value beyond standard risk assessment.

We rate the evidence moderate-limited. An observational validation study establishing LP-IR’s accuracy as an insulin resistance proxy from NMR data — useful for phenotyping in the research and advanced clinical context, but not yet established for routine practice.